中医药联合抗病毒预防乙型肝炎相关性肝硬变患者肝癌发生的相关研究  

Combination of Traditional Chinese Medicine and Antiviral Prophylaxis Against Hepatocarcinogenesis in Patients with Hepatitis B-related Hepatosteatosis

作　　者：徐兰玲 周文亮[1] 张世玺[1] 姚芳[1] Xu Lanling;Zhou Wenliang;Zhang Shixi;Yao Fang(Shangqiu No.1 People's Hospital Branch,Shangqiu 476000)

机构地区：[1]商丘市第一人民医院分院,商丘476000

出　　处：《数理医药学杂志》2021年第6期878-880,共3页Journal of Mathematical Medicine

摘　　要：目的:分析中医药联合抗病毒在乙型肝炎相关性肝硬变肝癌的预防及相关性。方法:收集2014年1月1日~2015年12月31日期间某院收治的300例乙肝相关性肝硬变患者作为研究对象,按照治疗方法分为对照组和观察组各150例,对照组采取西医治疗,观察组采取中西医结合治疗,随访5年,观察并比较两组患者的肝癌发生率。结果:治疗后,观察组患者各项生化指标水平均优于对照组(P<0.05);观察组癌变时间代偿期为(56.14±1.09)月、失代偿期为(51.38±1.21)月,对照组分别为(47.62±1.86)月、(46.72±1.55)月,差异有统计学意义(P<0.05),且在代偿期观察组癌变率(16.67%)明显低于对照组(27.50%)(P<0.05);两组失代偿期癌变率比较无明显差异(P>0.05)。两组CU-HCC评分中风险的癌变时间和癌变率比较无明显差异(P>0.05),观察组高风险的癌变时间(53.95±2.18)月、癌变率为(25.33%)、对照组分别为(47.66±2.84)月、(36.36%),差异均有统计学意义(P<0.05)。结论:乙型肝炎相关性肝硬变采用中医药联合抗病毒治疗,有效延缓病情进展,降低代偿期及高风险患者的肝癌发生率,延长癌变时间,具有积极预防作用。Objective:To analyze the prevention and relevance of Chinese medicine combined with antiviral in hepatitis B-related hepatosclerotic liver cancer.Methods:A total of 300 patients with hepatitis B-related hepatosclerosis treated in a hospital from 1 January 2014 to 31 December 2015 were recruited as research objects and divided into two groups according to the treatment method.150 patients in the control group were treated with western medicine,150 patients in the observation group were treated with combined traditional and western medicine,and they were followed up for 5 years to observe and compare the incidence of liver cancer between the two groups.Results:After treatment,the levels of all biochemical parameters of the patients in the observation group were better than those in the control group(P<0.05).In the observation group,the time of carcinogenesis compensation was(56.14±1.09)months,and the time of decompensation was(51.38±1.21)months,and those in the control group were(47.62±1.86)months and(46.72±1.55)months,respectively,with significant difference(P<0.05).The percentage of carcinogenesis during the compensatory stage in the observation group(16.67%)was significantly lower than that in the control group group(27.50%)(P<0.05),and there was no difference between the two groups in the rate of decompensated cancer(P>0.05).There was no difference in time to carcinogenesis and the rate of carcinogenesis of CU-HCC scores for risk between the two groups(P>0.05).The time to carcinogenesis for high risk in the observation group was(53.95±2.18)months,the rate of carcinogenesis in the observation group was 25.33%,thsoe in the control group were(47.66±2.84)months and 36.36%,respectively,and the difference between the two groups was statistically significant(P<0.05).Conclusion:The combination of traditional Chinese medicine(TCM)and antiviral therapy in the treatment of hepatitis B-related hepatosteatosis can effectively delay the progression of the disease,reduce the incidence of liver cancer in patients with co

关 键 词：乙型肝炎 肝癌 预防 中西联合治疗 

分 类 号：R575.1[医药卫生—消化系统]